Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin liposomal - Breath Therapeutics

X
Drug Profile

Ciclosporin liposomal - Breath Therapeutics

Alternative Names: Ciclosporin inhalation - Breath Therapeutics; Cyclosporine A Inhalation - Breath Therapeutics; L-CsA - Breath Therapeutics; L-CsA-i; Liposomal cyclosporine A - Breath Therapeutics

Latest Information Update: 04 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PARI
  • Developer Breath Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiolitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchiolitis obliterans
  • Phase II COVID-19 pneumonia

Most Recent Events

  • 01 May 2023 Breath Therapeutics completes a phase III BOSTON-1 trial in Bronchiolitis Obliterans in Austria, Belgium, France, Germany, Israel, Spain, USA and the UK (Inhalation)
  • 01 May 2023 Breath Therapeutics completes a phase III BOSTON-2 trial in Bronchiolitis Obliterans in Austria, Belgium, France, Germany, Israel, Spain, USA and the UK (Inhalation)
  • 18 Mar 2022 Breath Therapeutics terminates the phase II BOSTON-4 trial for Bronchiolitis Obliterans in France, Germany and Spain due to the low number of patients recruitment and the slow enrollment pace of patients (Inhalation) (NCT04107675)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top